CARsgen Therapeutics Introduced Zhuhai SB Xinchuang to Accelerate Allogeneic CAR-T Cell Products Development in Mainland China
SHANGHAI,Feb. 25,2025-- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK,"CARsgen Therapeutics"),a company focused on innovative CAR T-cell therapies for the treatment of hematolo